[시장보고서]인유두종바이러스(HPV) 검사 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 제품별, 기술별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

인유두종바이러스(HPV) 검사 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 제품별, 기술별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Human Papilloma Virus Testing Market Size, Share & Trends Analysis Report By Application (Cervical Cancer Screening, Vaginal Cancer Screening), By Product, By Technology, By End Use, By Region, And Segment Forecasts, 2025 - 2033

상품코드 : 1813883

리서치사 : Grand View Research

발행일 : 2025년 08월

페이지 정보 : 영문 110 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,590,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,034,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 12,922,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

인유두종바이러스(HPV) 검사 시장 요약

인유두종바이러스(HPV) 검사 시장 규모는 2024년 17억 6,000만 달러로 추정되며, 2033년에는 56억 7,000만 달러에 달할 것으로 예상되며, 2025년부터 2033년까지 CAGR 14.14%로 성장할 것으로 예상됩니다.

이 시장은 인유두종바이러스(HPV)가 자궁경부암의 95% 이상을 유발하는 HPV 관련 암의 증가로 인해 활성화되고 있습니다.

호주와 같은 국가에서는 더 높은 민감도를 위해 자궁경부암 검사를 HPV DNA 검사로 대체하고 있습니다. BD나 홀로직과 같은 셀프 샘플링 키트는 서비스가 충분히 제공되지 않는 지역에 대한 접근성을 확대하고 있습니다. 아프리카와 아시아에서는 WHO의 퇴치 전략과 NGO가 지원하는 프로그램이 보급을 촉진하고 있습니다. 분자진단의 발전, 번들형 여성 건강 패널, 실험실 인프라의 개선으로 전 세계적으로 검사 접근성이 향상되고 비용 효율성이 향상되고 있습니다. 자궁경부암은 전 세계 여성에게 4번째로 흔한 암이며, 여성 암 관련 사망 원인 중 2위를 차지합니다.

2020년 11월, 세계보건기구(WHO)는 '자궁경부암 퇴치를 위한 세계 전략'을 발표하고, 2030년까지 '90-70-90' 목표를 설정했다 - 15세까지 여아 90%에게 백신을 접종하고, 35세와 45세 여성의 70%를 검진하고, 질병이 확인된 여성의 90%를 치료합니다. 치료합니다. 2022년, 권장 검진 수검률 70% 이상에 도달한 국가는 18%에 불과하며, 전 세계 수검률은 아직 약 20%에 불과합니다. HPV는 자궁경부암 환자의 99.8%의 원인이며, 유전자형 16과 18형만 70%를 차지합니다. 19가지 고위험 유전자형이 HPV 관련 암의 90%를 차지합니다. HPV 감염은 대부분 무증상이기 때문에 조기 발견을 위해서는 분자 검사가 필수적입니다. 2017년 이후 호주, 네덜란드 등의 국가에서는 민감도가 높고 검진 간격이 길다는 이유로 자궁경부암 검사에서 1차 HPV DNA 검사로 전환하고 있습니다.

지역 시장 대시보드
지역별 시장 점유율 분석, 2021년 및 2033년
지역별 인유두종바이러스(HPV) 검사 시장 : 주요 포인트
북미
- 미국
- 캐나다
- 멕시코
유럽
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 한국
- 호주
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트

제9장 경쟁 구도

주요 시장 진입 기업의 최근 동향과 영향 분석
기업/경쟁 분류
벤더 상황
- Key Company Heat Map Analysis, 2024
기업 개요
- Abbott
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad Laboratories, Inc.
- Fujirebio
- Oncolab
- Hologic, Inc.
- Qiagen
- F. Hoffmann-La Roche Ltd
- Siemens Healthineers AG

KSM

영문 목차

영문목차

Human Papilloma Virus Testing Market Summary

The human papilloma virus testing market size was estimated at USD 1.76 billion in 2024 and is projected to reach USD 5.67 billion by 2033, growing at a CAGR of 14.14% from 2025 to 2033. The market is fueled by rising HPV-related cancer cases, with human papilloma virus (HPV) causing over 95% of cervical cancers.

Countries like Australia have replaced Pap smears with HPV DNA testing for higher sensitivity. Self-sampling kits, such as those from BD and Hologic, are expanding access in underserved areas. WHO's elimination strategy and NGO-backed programs in Africa and Asia drive adoption. Advances in molecular diagnostics, bundled women's health panels, and improved lab infrastructure make testing more accessible and cost-effective globally. Cervical cancer is the fourth most common cancer among women worldwide and the second leading cause of female cancer-related mortality.

In November 2020, the World Health Organization launched its Global Strategy to Eliminate Cervical Cancer, setting the 90-70-90 targets for 2030-vaccinate 90% of girls by age 15, screen 70% of women at ages 35 and 45, and treat 90% of women with identified disease. This initiative came against alarming statistics: in 2022, only 18% of countries had reached the recommended screening coverage of over 70%, and global coverage still stood at about 20%. HPV is the causative agent in 99.8% of cervical cancer cases, with genotypes 16 and 18 alone responsible for 70% of cases. Nineteen high-risk genotypes account for 90% of all HPV-related cancers. Given the asymptomatic nature of most HPV infections, molecular testing has become essential for early detection. Since 2017, countries such as Australia and the Netherlands have transitioned from Pap smears to primary HPV DNA testing, citing higher sensitivity and longer screening intervals.

Global Human Papilloma Virus Testing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global human papilloma virus (HPV) testing market report based on application, product, technology, end use, and region:

Application Outlook (Revenue, USD Million, 2021 - 2033)
Cervical Cancer Screening
Vaginal Cancer Screening
Product Outlook (Revenue, USD Million, 2021 - 2033)
Instruments
Consumables
Services
Technology Outlook (Revenue, USD Million, 2021 - 2033)
PCR
Immunodiagnostics
Others
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Hospitals & Clinics
Laboratories
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Application
- 1.2.2. Product
- 1.2.3. Technology
- 1.2.4. End Use
- 1.2.5. Regional Scope
- 1.2.6. Estimates and Forecasts Timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
- 1.4.5. Details of Primary Research
1.5. Information or Data Analysis
- 1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Application Outlook
- 2.2.2. Product Outlook
- 2.2.3. Technology Outlook
- 2.2.4. End Use Outlook
- 2.2.5. Regional Outlook
2.3. Competitive Scenario

Chapter 3. Human Papilloma Virus (HPV) Testing Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Human Papilloma Virus (HPV) Testing Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrant
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
  - 3.3.2.1. Political Landscape
  - 3.3.2.2. Technological Landscape
  - 3.3.2.3. Economic Landscape

Chapter 4. Human Papilloma Virus (HPV) Testing Market: Application Estimates & Trend Analysis

4.1. Application Segment Dashboard
4.2. Human Papilloma Virus (HPV) Testing Market: Application Movement Analysis
4.3. Global Human Papilloma Virus (HPV) Testing Market Size & Trend Analysis, By Application, 2021 - 2033 (USD Million)
4.4. Cervical Cancer Screening
- 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Vaginal Cancer Screening
- 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Human Papilloma Virus (HPV) Testing Market: Product Estimates & Trend Analysis

5.1. Product Segment Dashboard
5.2. Human Papilloma Virus (HPV) Testing Market: Product Movement Analysis
5.3. Global Human Papilloma Virus (HPV) Testing Market Size & Trend Analysis, By Product, 2021 - 2033 (USD Million)
5.4. Instruments
- 5.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Consumables
- 5.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Services
- 5.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Human Papilloma Virus (HPV) Testing Market: Technology Estimates & Trend Analysis

6.1. Technology Segment Dashboard
6.2. Human Papilloma Virus (HPV) Testing Market: Technology Movement Analysis
6.3. Global Human Papilloma Virus (HPV) Testing Market Size & Trend Analysis, By Technology, 2021 - 2033 (USD Million)
6.4. PCR
- 6.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Immunodiagnostics
- 6.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Others
- 6.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Human Papilloma Virus (HPV) Testing Market: End Use Estimates & Trend Analysis

7.1. End Use Segment Dashboard
7.2. Human Papilloma Virus (HPV) Testing Market: End Use Movement Analysis
7.3. Global Human Papilloma Virus (HPV) Testing Market Size & Trend Analysis, By End Use, 2021 - 2033 (USD Million)
7.4. Hospitals & Clinics
- 7.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Laboratories
- 7.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Others
- 7.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Human Papilloma Virus (HPV) Testing Market: Regional Estimates & Trend Analysis

8.1. Regional Market Dashboard
8.2. Regional Market Share Analysis, 2021 & 2033
8.3. Human Papilloma Virus (HPV) Testing Market by Region: Key Takeaways
8.4. North America
- 8.4.1. U.S.
  - 8.4.1.1. Key Country Dynamics
  - 8.4.1.2. Regulatory Framework/ Reimbursement Structure
  - 8.4.1.3. Competitive Scenario
  - 8.4.1.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.2. Canada
  - 8.4.2.1. Key Country Dynamics
  - 8.4.2.2. Regulatory Framework/ Reimbursement Structure
  - 8.4.2.3. Competitive Scenario
  - 8.4.2.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.3. Mexico
  - 8.4.3.1. Key Country Dynamics
  - 8.4.3.2. Regulatory Framework/ Reimbursement Structure
  - 8.4.3.3. Competitive Scenario
  - 8.4.3.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Europe
- 8.5.1. Germany
  - 8.5.1.1. Key Country Dynamics
  - 8.5.1.2. Regulatory Framework/ Reimbursement Structure
  - 8.5.1.3. Competitive Scenario
  - 8.5.1.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.2. UK
  - 8.5.2.1. Key Country Dynamics
  - 8.5.2.2. Regulatory Framework/ Reimbursement Structure
  - 8.5.2.3. Competitive Scenario
  - 8.5.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.3. France
  - 8.5.3.1. Key Country Dynamics
  - 8.5.3.2. Regulatory Framework/ Reimbursement Structure
  - 8.5.3.3. Competitive Scenario
  - 8.5.3.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.4. Italy
  - 8.5.4.1. Key Country Dynamics
  - 8.5.4.2. Regulatory Framework/ Reimbursement Structure
  - 8.5.4.3. Competitive Scenario
  - 8.5.4.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.5. Spain
  - 8.5.5.1. Key Country Dynamics
  - 8.5.5.2. Regulatory Framework/ Reimbursement Structure
  - 8.5.5.3. Competitive Scenario
  - 8.5.5.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.6. Denmark
  - 8.5.6.1. Key Country Dynamics
  - 8.5.6.2. Regulatory Framework/ Reimbursement Structure
  - 8.5.6.3. Competitive Scenario
  - 8.5.6.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.7. Sweden
  - 8.5.7.1. Key Country Dynamics
  - 8.5.7.2. Regulatory Framework/ Reimbursement Structure
  - 8.5.7.3. Competitive Scenario
  - 8.5.7.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.8. Norway
  - 8.5.8.1. Key Country Dynamics
  - 8.5.8.2. Regulatory Framework/ Reimbursement Structure
  - 8.5.8.3. Competitive Scenario
  - 8.5.8.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Asia Pacific
- 8.6.1. Japan
  - 8.6.1.1. Key Country Dynamics
  - 8.6.1.2. Regulatory Framework/ Reimbursement Structure
  - 8.6.1.3. Competitive Scenario
  - 8.6.1.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.2. China
  - 8.6.2.1. Key Country Dynamics
  - 8.6.2.2. Regulatory Framework/ Reimbursement Structure
  - 8.6.2.3. Competitive Scenario
  - 8.6.2.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.3. India
  - 8.6.3.1. Key Country Dynamics
  - 8.6.3.2. Regulatory Framework/ Reimbursement Structure
  - 8.6.3.3. Competitive Scenario
  - 8.6.3.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.4. South Korea
  - 8.6.4.1. Key Country Dynamics
  - 8.6.4.2. Regulatory Framework/ Reimbursement Structure
  - 8.6.4.3. Competitive Scenario
  - 8.6.4.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.5. Australia
  - 8.6.5.1. Key Country Dynamics
  - 8.6.5.2. Regulatory Framework/ Reimbursement Structure
  - 8.6.5.3. Competitive Scenario
  - 8.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.6. Thailand
  - 8.6.6.1. Key Country Dynamics
  - 8.6.6.2. Regulatory Framework/ Reimbursement Structure
  - 8.6.6.3. Competitive Scenario
  - 8.6.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. Latin America
- 8.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.2. Brazil
  - 8.7.2.1. Key Country Dynamics
  - 8.7.2.2. Regulatory Framework/ Reimbursement Structure
  - 8.7.2.3. Competitive Scenario
  - 8.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.3. Argentina
  - 8.7.3.1. Key Country Dynamics
  - 8.7.3.2. Regulatory Framework/ Reimbursement Structure
  - 8.7.3.3. Competitive Scenario
  - 8.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8. Middle East and Africa
- 8.8.1. Middle East and Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.2. South Africa
  - 8.8.2.1. Key Country Dynamics
  - 8.8.2.2. Regulatory Framework/ Reimbursement Structure
  - 8.8.2.3. Competitive Scenario
  - 8.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.3. Saudi Arabia
  - 8.8.3.1. Key Country Dynamics
  - 8.8.3.2. Regulatory Framework/ Reimbursement Structure
  - 8.8.3.3. Competitive Scenario
  - 8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.4. UAE
  - 8.8.4.1. Key Country Dynamics
  - 8.8.4.2. Regulatory Framework/ Reimbursement Structure
  - 8.8.4.3. Competitive Scenario
  - 8.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.5. Kuwait
  - 8.8.5.1. Key Country Dynamics
  - 8.8.5.2. Regulatory Framework/ Reimbursement Structure
  - 8.8.5.3. Competitive Scenario
  - 8.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/ Competition Categorization
9.3. Vendor Landscape
- 9.3.1. Key Company Heat Map Analysis, 2024
9.4. Company Profiles
- 9.4.1. Abbott
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Financial Performance
  - 9.4.1.3. Product Benchmarking
  - 9.4.1.4. Strategic Initiatives
- 9.4.2. Biomedical Diagnostics
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Financial Performance
  - 9.4.2.3. Product Benchmarking
  - 9.4.2.4. Strategic Initiatives
- 9.4.3. bioMerieux
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Financial Performance
  - 9.4.3.3. Product Benchmarking
  - 9.4.3.4. Strategic Initiatives
- 9.4.4. Bio-Rad Laboratories, Inc.
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Financial Performance
  - 9.4.4.3. Product Benchmarking
  - 9.4.4.4. Strategic Initiatives
- 9.4.5. Fujirebio
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Financial Performance
  - 9.4.5.3. Product Benchmarking
  - 9.4.5.4. Strategic Initiatives
- 9.4.6. Oncolab
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Financial Performance
  - 9.4.6.3. Product Benchmarking
  - 9.4.6.4. Strategic Initiatives
- 9.4.7. Hologic, Inc.
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Financial Performance
  - 9.4.7.3. Product Benchmarking
  - 9.4.7.4. Strategic Initiatives
- 9.4.8. Qiagen
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Financial Performance
  - 9.4.8.3. Product Benchmarking
  - 9.4.8.4. Strategic Initiatives
- 9.4.9. F. Hoffmann-La Roche Ltd
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Financial Performance
  - 9.4.9.3. Product Benchmarking
  - 9.4.9.4. Strategic Initiatives
- 9.4.10. Siemens Healthineers AG
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Financial Performance
  - 9.4.10.3. Product Benchmarking
  - 9.4.10.4. Strategic Initiatives

한글목차

인유두종바이러스(HPV) 검사 시장 요약

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 인유두종바이러스(HPV) 검사 시장 변수, 동향, 범위

제4장 인유두종바이러스(HPV) 검사 시장 : 용도 추정·동향 분석

제5장 인유두종바이러스(HPV) 검사 시장 : 제품 추정·동향 분석

제6장 인유두종바이러스(HPV) 검사 시장 : 기술 추정·동향 분석

제7장 인유두종바이러스(HPV) 검사 시장 : 최종 용도 추정·동향 분석

제8장 인유두종바이러스(HPV) 검사 시장 : 지역 추정·동향 분석